ADVFN Logo

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

IGC IGC Pharma Inc

0,4151
0,0086 (2,12%)
Avant marché
Dernière mise à jour : 13:18:02
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
IGC Pharma Inc IGC AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,0086 2,12% 0,4151 13:18:02
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,4065
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
26/3/202420:00BWIGC Pharma Announces $3 Million Unregistered Private..
20/3/202416:00BWIGC Pharma Announces Positive Interim Results for IGC-AD1 in..
20/3/202412:00BWIGC PHARMA Announces its Participation at the Benzinga..
12/3/202420:00BWIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins..
28/2/202419:00BWPromising Results: TGR-63 Enhances Memory in Alzheimer's..
23/2/202418:01BWIGC Pharma Announces Equity Analyst Coverage by Ascendiant..
17/2/202401:05BWIGC Pharma Reports Third Quarter Fiscal 2024 Results
14/2/202422:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/2/202415:20BWIGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's..
31/1/202422:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23/1/202415:20BWIGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63..
17/1/202415:20BWIGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing..
09/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
29/12/202322:54EDGAR2Form S-3 - Registration statement under Securities Act of..
19/12/202315:20BWPatent Granted to IGC Pharma for Groundbreaking Drug..
13/12/202315:30BWIGC Pharma Announces Participation in Biotech Showcase and..
06/12/202314:30BWIGC Pharma Announces Collaboration to Integrate AI into..
21/11/202314:30BWIGC Pharma Announces Master Agreement with Leading South..
13/11/202314:00BWIGC Pharma Reports Second Quarter Fiscal 2024 Results
09/11/202323:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
27/10/202323:21EDGAR2Form 8-K - Current report
27/10/202322:38EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/10/202321:30BWIGC Pharma Granted European Patent for Groundbreaking..
29/9/202323:23EDGAR2Form S-3 - Registration statement under Securities Act of..
21/8/202320:30BWIGC Announces Results of its 2023 Annual Stockholders..
21/8/202318:44EDGAR2Form 8-K - Current report
14/8/202314:30BWIGC Pharma Reports First Quarter Results; Company Continues..
10/8/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/8/202314:30BWIGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the..
26/7/202323:26EDGAR2Form DEF 14A - Other definitive proxy statements
18/7/202311:22BWIGC Pharma, Inc. Presenting 6 Posters on the Positive Impact..
12/7/202314:44BWIGC Reports Financial Results for Fiscal Year Ended March..
07/7/202322:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/7/202317:41EDGAR2Form 8-K - Current report
07/7/202315:15BWIGC Pharma Secures $12 Million Line of Credit from O-Bank..
06/7/202313:46BWIGC Pharma Announces a $3 Million Private Placement of its..
30/6/202322:03EDGAR2Form NT 10-K - Notification of inability to timely file Form..
29/6/202303:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/6/202319:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202315:20BWIGC Pharma Receives Notice of Allowance for Patent on..
05/6/202314:30BWIGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63..

Dernières Valeurs Consultées

Delayed Upgrade Clock